EUCTR2007-004466-41-HU进行中（未招募）不适用
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - N/A
Pfizer Ltd, Ramsgate Road, Sandwich, Kent0 个研究点目标入组 640 人开始时间: 2009年2月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects between, and including, the ages of 40 and 80 years. Females must be of non-childbearing potential. Females of non-child-bearing potential will be defined as:
- •Females over the age of 60 years.
- •Females who are 45-60 years of age who have been amenorrheic for at least 2 years and have a serum FSH level >30 IU/L in the absence of hormone replacement therapy or have a documented hysterectomy and/or bilateral oophrectomy.
- •2. Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease:
- •Subjects must have a post-bronchodilator FEV1/FVC ratio < 0.7 and a postbronchodilator FEV1 of 30 - 80% (inclusive) of the predicted value for age, height, race and sex using European Community for Coal and Steel ECCS standards. To qualify for randomization, these criteria must be met at Screening and replicated during run-in phase.
- •3. Subjects must have a smoking history of at least 10 pack-years* and meet one of the following criteria:
- •They are current smokers or
- •They are ex-smokers who have abstained from smoking for at least 6 months.
- •*Formula for pack-years:
- •cigarettes = (average number of cigarettes/day ÷ 20) x years of smoking.
- •tobacco = ounces per week x 2/7 x years of smoking.
- •4. Subjects must have had stable disease for at least 1 month prior to screening. During the screening and run-in phase subjects must be able to manage disease symptoms adequately with short-acting bronchodilators only [i.e. inhaled ipratropium bromide 2 actuations (20µg /actuation) QID administered from a MDI +/- salbutamol (albuterol) rescue medication up to a maximum of 8 actuations (100µg /actuation) daily], without reliance on other therapies including oral or inhaled corticosteroids, long-acting bronchodilators, nebulizer therapy, theophylline or regular oxygen.
- •5. Body Mass Index (BMI) < 35 kg/m2 and a total body weight >40 kg.
- •6. Subjects must be able to give informed, written consent prior to entering the study.
- •7. Subjects must be willing and able to comply with scheduled visit and all study-related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalization for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
- •2.History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomization.
- •3. History or presence of respiratory failure, cor pulmonale or right ventricular failure.
- •4.Subjects with home oxygen therapy (either PRN or long-term oxygen therapy).
- •5.Any clearly documented history of adult asthma or other chronic respiratory disorders (e.g. bronchiectasis, pulmonary fibrosis, pneumoconiosis).
- •6.Known previous diagnosis of HIV infection.
- •7.History of cancer (other than cutaneous basal cell) in the previous 5 years.
- •8.History within the previous 2 years of: myocardial infarction, cardiac arrhythmia (e.g. atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia), left ventricular failure, congestive cardiac failure, unstable angina, coronary angioplasty, coronary artery bypass grafting (CABG) or cerebrovascular accident (including transient ischemic attacks).
- •9.Tuberculosis without treatment and/or positive tuberculin reaction to PPD (Purified Protein Deriviative) without known (documented) vaccination with the bacilli Calmette-Guerin vaccine (BCG). A positive approved immunoassay/ELIA blood test for TB (e.g. TB T-SPOT, QuantiFERON-Gold test) where used.
- •10.History within the previous 6 months of:
- •An epileptic seizure.
- •Poorly controlled Type 1 or Type 2 diabetes.
- •Acute hepatitis of any aetiology.
- •11.Presenting with:
- •Any condition possibly affecting oral drug absorption (e.g. gastrectomy or clinically significant diabetic gastroenteropathy);
- •Any clinically significant skin lesions as described in Common Terminology Criteria for Adverse Events for Dermatology (CTCAE) Version 3.0.;
- •Any clinically significant active infection including herpetic lesions;
- •Congestive heart failure requiring treatment New York Heart Association (NYHA) Class III-IV;
- •12.A major surgical operation within 1 month of screening.
- •13.ECG abnormalities at screening or randomization, including those listed below. The investigator will decide whether ECG abnormalities other than those listed are clinically significant and should exclude the subject from enrolment if abnormality is considered to be clinically significant:
- •Subjects with pre-randomization evidence of QTc prolongation at screening or baseline Week 0 (defined as >450 ms) are not eligible for randomization. This assessment is based on a confirmed mean of the triplicate ECG recordings and is made by the investigator at the time of ECG collection.
- •Predominant heart rhythm other than normal sinus rhythm e.g. atrial fibrillation, atrial flutter, supraventricular tachycardia.
- •Atrioventricular (AV) block greater than first degree.
- •Resting heart rate >100 or <40 bpm.
- •Evidence of previous myocardial infarction in the absence of clinical history consistent with these findings.
- •Evidence of acute ischaemia.
- •14.History or evidence, based upon a complete medical history, full physical examination, posterior-anterior chest X-ray (within last 12 months), 12-lead resting ECG or clinical laboratory test results, of any other significant concomitant clinical disease that, in the opinion of the investigator, could
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients with Severe Covid-19 PneumoniaSevere coronavirus disease 2019 (COVID-19) pneumoniaMedDRA version: 23.0Level: LLTClassification code 10084383Term: Novel COVID-19-infected pneumoniaSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 100000004862EUCTR2020-002713-17-ESGenentech, Inc.300
招募中
2 期
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LUPUS NEPHRITIS, INCLUDING AN EVALUATION OF OPEN LABEL SAFETY AND PK IN A COHORT OF PEDIATRIC PATIENTS (AGED 5 to < 12).11 NULLN118 Other chronic tubulo-interstitial nephritisOther chronic tubulo-interstitial nephritisN118PER-051-21F. HOFFMANN-LA ROCHE LTD.2
进行中（未招募）
1 期
A STUDY OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE ASTHMA WHO DEPEND ON ORAL CORTICOSTEROIDS.AsthmaEUCTR2012-000190-24-NLF. Hoffmann-La Roche Ltd225
进行中（未招募）
1 期
A STUDY OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE ASTHMA WHO DEPEND ON ORAL CORTICOSTEROIDS.MedDRA version: 18.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2012-000190-24-PLF. Hoffmann-La Roche Ltd225
进行中（未招募）
1 期
A STUDY OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE ASTHMA WHO DEPEND ON ORAL CORTICOSTEROIDS.MedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2012-000190-24-CZF. Hoffmann-La Roche Ltd225